How to deal with an unexpected event that could alter the normal activity of cellular therapy? Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Copyright © 2021. Published by Elsevier Masson SAS..
The SARS-CoV-2 (COVID-19) pandemic has rapidly impacted cell therapy activities across the globe. Not only was this, unexpected event, a threat to patients who had previously received hematopoietic cell transplantation or other cell therapy such as CAR-T cells, but also, it was responsible for a disruption of cell therapy activities due to the danger of the virus and to the lack of solid scientific data on the management of patients and donors. The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) devoted a workshop to issue useful recommendations in such an unexpected event in order to harmonize the actions of all the actors involved in cellular therapy programs so that we can collectively face, in the future, the challenges that could threaten our patients. This work is not specifically dedicated to the SARS-CoV-2 outbreak, but the latter has been used as a concrete example of an unexpected event to build up our recommendations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 108(2021), 12S vom: 16. Dez., Seite S20-S25 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Comment faire face à un événement inattendu pouvant modifier l’activité normale de thérapie cellulaire ? Recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) |
|---|
| Beteiligte Personen: |
Bay, Jacques Olivier [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.12.2021 Date Revised 29.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2021.05.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327621028 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327621028 | ||
| 003 | DE-627 | ||
| 005 | 20231225201205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2021.05.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327621028 | ||
| 035 | |a (NLM)34215432 | ||
| 035 | |a (PII)S0007-4551(21)00222-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Bay, Jacques Olivier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How to deal with an unexpected event that could alter the normal activity of cellular therapy? Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) |
| 246 | 3 | 3 | |a Comment faire face à un événement inattendu pouvant modifier l’activité normale de thérapie cellulaire ? Recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2021 | ||
| 500 | |a Date Revised 29.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Masson SAS. | ||
| 520 | |a The SARS-CoV-2 (COVID-19) pandemic has rapidly impacted cell therapy activities across the globe. Not only was this, unexpected event, a threat to patients who had previously received hematopoietic cell transplantation or other cell therapy such as CAR-T cells, but also, it was responsible for a disruption of cell therapy activities due to the danger of the virus and to the lack of solid scientific data on the management of patients and donors. The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) devoted a workshop to issue useful recommendations in such an unexpected event in order to harmonize the actions of all the actors involved in cellular therapy programs so that we can collectively face, in the future, the challenges that could threaten our patients. This work is not specifically dedicated to the SARS-CoV-2 outbreak, but the latter has been used as a concrete example of an unexpected event to build up our recommendations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allogeneic/autologous hematopoietic cell transplantation | |
| 650 | 4 | |a Allogreffe/autogreffe de cellules souches hématopoïétiques | |
| 650 | 4 | |a CAR-T Cells | |
| 650 | 4 | |a Cellules CAR-T | |
| 650 | 4 | |a Disaster plan | |
| 650 | 4 | |a Plan d’urgence sanitaire | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Unexpected event | |
| 650 | 4 | |a Évènements inattendus | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Beguin, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Carpentier, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Dard, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Guillaume, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Labussiere-Wallet, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Lacassagne, Marie Noëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Sauze, Séverine |e verfasserin |4 aut | |
| 700 | 1 | |a Yakoub-Agha, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Chalandon, Yves |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 108(2021), 12S vom: 16. Dez., Seite S20-S25 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2021 |g number:12S |g day:16 |g month:12 |g pages:S20-S25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2021.05.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2021 |e 12S |b 16 |c 12 |h S20-S25 | ||